论文部分内容阅读
目的比较双时相门冬胰岛素(诺和锐30)与预混人胰岛素(诺和灵30R)治疗2型糖尿病的临床疗效和安全性。方法采用每天两次的注射方法,选取口服药控制不佳的2型糖尿病患者62例,随机分为诺和锐30治疗组和诺和灵30R治疗组,进行为期30d的治疗,观察两组患者4个时点的血糖(空腹及三餐后2h)、糖化血红蛋白、低血糖事件的差异。结果诺和锐30治疗组空腹、三餐后血糖水平低于诺和灵30R治疗组(P<0.05);诺和锐30治疗组低血糖发生次数低于诺和灵30R治疗组;糖化血红蛋白水平无统计学差异。结论诺和锐30在疗效及安全性更优于诺和灵30R。
Objective To compare the clinical efficacy and safety of double-phase aspart insulin (Novo-Rui-30) and premixed insulin (Novo-Ling 30R) in the treatment of type 2 diabetes mellitus. Methods Sixty-two patients with type 2 diabetes with poor oral control were enrolled in this study. The patients were randomly divided into Nuo-Rui-Rui-30 treatment group and Novolin-30R treatment group for 30 days. Two groups of patients 4 points of blood sugar (fasting and after meals, 2h), HbAlc, hypoglycemic events. Results In Novo-Rui-30 treatment group, fasting blood glucose level after three meals was lower than that of Novolin 30R treatment group (P <0.05); the incidence of hypoglycemia in Novo-Rui-30 treatment group was lower than that of Novolin 30R treatment group; the level of glycosylated hemoglobin No statistical difference. Conclusion Novo Rui 30 in the efficacy and safety is better than Novo-30R.